BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355

Like
Comment
Favorite

BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355

Reuters01-20

Jan 20 (Reuters) - Keymed Biosciences 2162.HK:

LICENSE AGREEMENT WITH PROLIUM FOR DEVELOPMENT AND COMMERCIALIZATION OF CM355
CHENGDU KEYMED AND BEIJING INNOCARE WILL RECEIVE $17.5 MILLION, AND ADDITIONAL PAYMENTS UP TO US$502.5 MILLION

Further company coverage: 2162.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

22:28
Trump Signs Order Imposing Sanctions on Countries Importing Venezuelan Oil -White House
22:25
Mastermyne Group - Contract Encompasses Approximately 200 Roles at Appin Mine, Others
22:25
Mastermyne Group - Executed Contract for Contract Mining Services With Gear M Illawarra Met Coal
22:20
Fortis Inc - Net Proceeds to Reduce Borrowings and for General Corporate Purposes
22:20
Fortis Inc - Prices $600 Million Offering of 4.090% Senior Unsecured Notes Due 2032

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2504477932?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-01-20 18:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2504477932","market":"us","top_or_hot":-1,"title":"BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355</title></head><body><p><span>Jan 20 (Reuters)</span><span> - </span>Keymed Biosciences <span>2162.HK</span>:</p><ul><li><p>LICENSE AGREEMENT WITH PROLIUM FOR DEVELOPMENT AND COMMERCIALIZATION OF CM355</p></li><li><p>CHENGDU KEYMED AND BEIJING INNOCARE WILL RECEIVE $17.5 MILLION,  AND ADDITIONAL PAYMENTS UP TO US$502.5 MILLION</p></li></ul><p>Further company coverage: <span>2162.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Keymed Biosciences Reports Agreement For Development Of CM355\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-20 18:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355</title></head><body><p><span>Jan 20 (Reuters)</span><span> - </span>Keymed Biosciences <span>2162.HK</span>:</p><ul><li><p>LICENSE AGREEMENT WITH PROLIUM FOR DEVELOPMENT AND COMMERCIALIZATION OF CM355</p></li><li><p>CHENGDU KEYMED AND BEIJING INNOCARE WILL RECEIVE $17.5 MILLION,  AND ADDITIONAL PAYMENTS UP TO US$502.5 MILLION</p></li></ul><p>Further company coverage: <span>2162.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250120:nFWN3OE0AO:1","article_id":"2504477932","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2504477932","pubTimestamp":1737367969,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355Jan 20  - Keymed Biosciences 2162.HK:LICENSE AGREEMENT WITH PROLIUM FOR DEVELOPMENT AND COMMERCIALIZATION OF CM355CHENGDU KEYMED AND BEIJING INNOCARE WILL RECEIVE $17.5 MILLION,  AND ADDITIONAL PAYMENTS UP TO US$502.5 MILLIONFurther company coverage: 2162.HK ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B","BK1161":"生物科技","BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念"},"translate_title":"简报-Keymed Biosciences报告CM355开发协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9},"content_text":"BRIEF-Keymed Biosciences Reports Agreement For Development Of CM355Jan 20 (Reuters) - Keymed Biosciences 2162.HK:LICENSE AGREEMENT WITH PROLIUM FOR DEVELOPMENT AND COMMERCIALIZATION OF CM355CHENGDU KEYMED AND BEIJING INNOCARE WILL RECEIVE $17.5 MILLION,  AND ADDITIONAL PAYMENTS UP TO US$502.5 MILLIONFurther company coverage: 2162.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}